Dr Jones speaks at EONS 10, considering the side effects of CDK inhibition, including a class-wide tendency towards neutropenia, and how they might be managed with dose interruption.
CDKs were also discussed at an ecancer symposium at ESMO 2016.
Supported by a grant from Pfizer Inc.